Amplia's Cancer Program
Focal Adhesion Kinase (FAK) is directly involved in several important biological processes including in the formation of new fibrotic tissues and the migration of cells. When cancers become established in the body, they often use these processes to improve their own survival:
- Fibrosis: many cancers surround themselves with dense, fibrotic tissue that protects them from the immune system and can stop drugs from reaching them
- Migration: as cancers grow, cancer cells can migrate to other parts of the human body (metastasis) which often is the cause of death in cancer patients
Amplia’s Cancer Program is directed at using its FAK inhibitors to block fibrosis and cell migration in cancers in order to make them more vulnerable and responsive to currently used treatment regimens.
Amplia is planning to initiate a Phase 2 clinical trial of AMP945 in combination with the current standard of care (gemcitabine/Abraxane®) in patients with pancreatic cancers in late 2021.